Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACR | P10323 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245237 | 1.00 | ADORA1 (0.43) | ADORA1ADORA2AADORA3ADORA2BTACR3 | |
| SCHEMBL2105173 | 0.87 | ACACB (0.34) | ADORA1ADORA2AADORA3ADORA2BTACR3 | |
| SCHEMBL19824617 | 0.83 | ADORA1 (0.38) | ADORA1ADORA2AADORA3ADORA2BTACR3 | |
| SCHEMBL18055587 | 0.83 | SSTR3 (0.43) | ADORA1ADORA2AADORA3ADORA2BMAPT | |
| SCHEMBL19812528 | 0.83 | SSTR3 (0.43) | ADORA1ADORA2AADORA3ADORA2BMAPT | |
| SCHEMBL4242275 | 0.82 | CNR2 (0.43) | ADORA1ADORA2AADORA3ADORA2BALDH1A1 | |
| SCHEMBL4242271 | 0.82 | CNR2 (0.43) | ADORA1ADORA2AADORA3ADORA2BALDH1A1 | |
| SCHEMBL1928985 | 0.82 | CNR1 (0.40) | ADORA1ADORA2AADORA3ADORA2BTACR3 | |
| SCHEMBL19829076 | 0.81 | TDP1 (0.40) | ADORA1ADORA2AADORA3ADORA2BALDH1A1 | |
| SCHEMBL2341611 | 0.81 | TACR3 (0.44) | ADORA1ADORA2AADORA3ADORA2BTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479769-B2 | Processes for the preparation of eluxadoline | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2019-11-19 | — | — | US | disclosed |
| US-20190248748-A1 | PROCESSES FOR THE PREPARATION OF ELUXADOLINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248748-A1 | PROCESSES FOR THE PREPARATION OF ELUXADOLINE | CYP3A5, AVPR2, CYP3A4 | ADORA1 547/4885ADORA2A 644/4885ADORA3 214/4885 |
| US-10479769-B2 | Processes for the preparation of eluxadoline | CYP3A5, AVPR2, CYP3A4 | ADORA1 547/4885ADORA2A 644/4885ADORA3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.